Skip to content
Head to head

Tango Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: TNGX · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

TNGX +172.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
TNGXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price21.73515.02
Change today-4.32%-1.08%
1-year return+144.2%+22.0%
Market cap$3.68B$130.58B
52-week range8.30 – 34.39412.27 – 568.67
Valuation
P/E (TTM)-15.7533.14
P/E percentile, own 5-yr range14th99th
P/B3.766.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.8715.32
Net profit (TTM)$-147.43M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-100.0%+11.8%
Gross margin--85.5%
Operating margin-253.4%33.1%
Net margin-229.9%30.7%
Free cash flow (TTM)$-150.36M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership136.6%96.8%
Insider activity (12mo)25 buy / 22 sell28 buy / 22 sell
Short interest (% of float)28.6%1.9%
Analyst consensus100% buy (6)95% buy / 5% hold (21)
Analyst price target$49 (+124%)$624 (+21%)
StockVane view
StockVane Quant RatingD (99)C (68)
Company
Employees1376,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.